US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

Seer, Inc. - Class A Common Stock (NQ:SEER)

2.210 +0.020 (+0.91%)
Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seer, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries
23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product Suite 
From Seer, Inc.
Via GlobeNewswire
News headline image
The Radoff-JEC Group Sends Open Letter to Seer, Inc. Unconflicted Independent Directors Meeta Gulyani and Nicolas Roelofs
From On Behalf of The Radoff-JEC Group
Via Business Wire
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Seer (SEER) Q4 2025 Earnings Call Transcript ↗
Seer (SEER) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Seer Inc. (NASDAQ:SEER) Shares Plunge on Weak 2026 Revenue Guidance ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook
From Seer, Inc.
Via GlobeNewswire
News headline image
The Radoff-JEC Group Issues Open Letter to Seer Inc.’s Board of Directors Regarding the Immediate Need for Significant Change
From On Behalf of The Radoff-JEC Group
Via Business Wire
News headline image
Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights 
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Participate in the TD Cowen 46th Annual Health Care Conference
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From Seer, Inc.
Via GlobeNewswire
News headline image
Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers
Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches,... 
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025
Studies spanning cardiovascular, aging, and cancer biology highlight how Seer’s Proteograph® platform is enabling discovery at population scale 
From Seer, Inc.
Via GlobeNewswire
News headline image
SEER INC (NASDAQ:SEER) Reports Q3 2025 Results with Narrow Revenue Beat and Reduced Losses ↗
Seer Inc (SEER) reports Q3 2025 results with a narrow revenue beat and reduced net losses, driven by robust demand for its Proteograph workflow. 
Via Chartmill
News headline image
Seer Reports Third Quarter 2025 Financial Results
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Participate in Upcoming November Investor Conferences
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Report Third Quarter 2025 Financial Results on November 6, 2025
From Seer, Inc.
Via GlobeNewswire
News headline image
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025
Scientific presentations reveal how Seer’s Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers 
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Appoints Isaac Ro to its Board of Directors
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer (SEER) Q2 Revenue Jumps 32% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Seer (SEER) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings World Trade
News headline image
Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Report Second Quarter 2025 Financial Results on August 6, 2025
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
From Seer, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >